The chimeric adenovirus (Ad5/35) expressing engineered spike Protein confers immunity against SARS-CoV-2 in mice and non-human primates

Cited 3 time in scopus
Metadata Downloads
Title
The chimeric adenovirus (Ad5/35) expressing engineered spike Protein confers immunity against SARS-CoV-2 in mice and non-human primates
Author(s)
S P Shin; K S Shin; J M Lee; I K Jung; J Koo; S W Lee; S Park; J Shin; M Park; B Park; Hanseul Oh; Bon-Sang KooJungjoo HongChoong-Min Ryu; J O Kim; T Oh; C Y Kang
Bibliographic Citation
Vaccines, vol. 10, no. 5, pp. 712-712
Publication Year
2022
Abstract
Several COVID-19 platforms have been licensed across the world thus far, but vaccine platform research that can lead to effective antigen delivery is still ongoing. Here, we constructed AdCLD-CoV19 that could modulate humoral immunity by harboring SARS-CoV-2 antigens onto a chimeric adenovirus 5/35 platform that was effective in cellular immunity. By replacing the S1/S2 furin cleavage sequence of the SARS-CoV-2 Spike (S) protein mounted on AdCLD-CoV19 with the linker sequence, high antigen expression was confirmed in various cell lines. The high levels of antigen expression contributed to antigen-specific antibody activity in mice and non-human primates (NHPs) with a single vaccination of AdCLD-CoV19. Furthermore, the adenovirus-induced Th1 immune response was specifically raised for the S protein, and these immune responses protected the NHP against live viruses. While AdCLD-CoV19 maintained neutralizing antibody activity against various SARS-CoV-2 variants, it was reduced to single vaccination for β and ο variants, and the reduced neutralizing antibody activity was restored with booster shots. Hence, AdCLD-CoV19 can prevent SARS-CoV-2 with a single vaccination, and the new vaccine administration strategy that responds to various variants can maintain the efficacy of the vaccine.
Keyword
SARS-CoV-2VariantsCOVID-19 vaccineChimeric adenovirus-vectored vaccineGS linkerNeutralizing activityTh1 immune responses
ISSN
2076-393X
Publisher
MDPI
DOI
http://dx.doi.org/10.3390/vaccines10050712
Type
Article
Appears in Collections:
Ochang Branch Institute > Division of National Bio-Infrastructure > National Primate Research Center > 1. Journal Articles
Division of Research on National Challenges > Infectious Disease Research Center > 1. Journal Articles
Files in This Item:
  • There are no files associated with this item.


Items in OpenAccess@KRIBB are protected by copyright, with all rights reserved, unless otherwise indicated.